MacroChem CEO Will Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 28 in New York LEXINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- MacroChem Corporation (NasdaqSC: MCHM), a specialty pharmaceutical company, has announced that Robert J. DeLuccia, president and chief executive officer, will review the company's clinical-program status and business strategy at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference, being held this week at The Waldorf Astoria in New York. More than 200 public and private companies will present to institutional investors, venture capitalists and pharmaceutical executives attending the conference. In his presentation, scheduled for October 28 at 11:50 AM, Mr. DeLuccia will review the MacroChem business strategy -- the development and commercialization of innovative products that capitalize on the company's proprietary transdermal drug delivery technology, SEPA(R). He will also discuss the company's two SEPA-enhanced products currently in clinical development -- Opterone(R), a topical testosterone cream for treating male hypogonadism, and EcoNail(TM), an econazole nail lacquer for treating onychomycosis (fungal infections of nails). MacroChem expects to begin a planned bioavailability study of Opterone this quarter. Its current Phase 1 safety/tolerance trial of EcoNail in patients with onychomycosis is fully enrolled, and MacroChem expects trial sites to complete the treatment phase by the end of 2004. This presentation is being webcast by CCBN and can be accessed at the MacroChem web site, http://www.macrochem.com/. The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the presentation through CCBN's individual investor center at http://www.fulldisclosure.com/ or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (http://www.fulldisclosure.com/). The web address of MacroChem's presentation is http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MCHM&item_id=949877 About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA: Opterone(TM), a SEPA-enhanced topical treatment for male hypogonadism; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Media Contact: Bernard Patriacca Donna LaVoie VP/CFO (LaVoie Group) (781) 862-4003 (781) 596-0200 x103 DATASOURCE: MacroChem Corporation CONTACT: Investor Contact, Bernard Patriaccam, VP/CFO of MacroChem, +1-781-862-4003; or Media Contact, Donna LaVoie of LaVoie Group, +1-781-596- 0200 ext. 103 Web site: http://www.macrochem.com/

Copyright